PL3503890T3 - Stosowanie pridopidyny w leczeniu dystonii - Google Patents

Stosowanie pridopidyny w leczeniu dystonii

Info

Publication number
PL3503890T3
PL3503890T3 PL17844432.9T PL17844432T PL3503890T3 PL 3503890 T3 PL3503890 T3 PL 3503890T3 PL 17844432 T PL17844432 T PL 17844432T PL 3503890 T3 PL3503890 T3 PL 3503890T3
Authority
PL
Poland
Prior art keywords
pridopidine
dystonia
treatment
Prior art date
Application number
PL17844432.9T
Other languages
English (en)
Polish (pl)
Inventor
Michael Hayden
Spyridon Papapetropoulos
Juha-Matti Savola
Eli Eyal
Beth Borowsky
Igor D. Grachev
Mark Forrest Gordon
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3503890T3 publication Critical patent/PL3503890T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17844432.9T 2016-08-24 2017-08-24 Stosowanie pridopidyny w leczeniu dystonii PL3503890T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395319P 2016-09-15 2016-09-15
PCT/US2017/048458 WO2018039475A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating dystonias

Publications (1)

Publication Number Publication Date
PL3503890T3 true PL3503890T3 (pl) 2025-03-24

Family

ID=61246309

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17844432.9T PL3503890T3 (pl) 2016-08-24 2017-08-24 Stosowanie pridopidyny w leczeniu dystonii

Country Status (12)

Country Link
US (2) US11826361B2 (enExample)
EP (1) EP3503890B1 (enExample)
JP (2) JP7278210B2 (enExample)
CN (1) CN110012661A (enExample)
AU (1) AU2017315781B2 (enExample)
BR (1) BR112019003731A2 (enExample)
CA (1) CA3035099C (enExample)
DK (1) DK3503890T3 (enExample)
ES (1) ES3009437T3 (enExample)
MX (1) MX2019002190A (enExample)
PL (1) PL3503890T3 (enExample)
WO (1) WO2018039475A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
MX383462B (es) 2017-09-08 2025-03-14 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
BR112022022427A2 (pt) * 2020-05-04 2022-12-13 Prilenia Neurotherapeutics Ltd Tratamento de infecção, doença ou distúrbio viral com o uso de um agonista de s1r seletivo
AU2023420087A1 (en) * 2022-12-27 2025-07-10 Prilenia Neurotherapeutics Ltd. Pridopidine for treating juvenile huntington's disease
WO2024258929A1 (en) * 2023-06-12 2024-12-19 Unravel Biosciences, Inc. Methods for treating diseases associated with taf1 loss of function
US20250281500A1 (en) * 2024-03-06 2025-09-11 Ovid Therapeutics Inc. Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
DK1773772T3 (da) * 2004-06-08 2010-09-13 Nsab Af Neurosearch Sweden Ab Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
BRPI0810161A2 (pt) 2007-04-12 2014-12-30 Nsab Af Neurosearch Sweden Ab Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
EA027748B1 (ru) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
HUE058288T2 (hu) * 2014-01-22 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin módosított hatóanyag-leadású készítményei
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
PL3419622T3 (pl) 2016-02-24 2024-07-08 Prilenia Neurotherapeutics Ltd. Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
JP2019529411A (ja) 2016-09-15 2019-10-17 プリレニア ニューロセラピューティクス リミテッド 不安症およびうつ病の治療のためのプリドピジンの使用
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2986807T3 (es) 2016-09-16 2024-11-12 Prilenia Neurotherapeutics Ltd Pridopidina para su uso en el tratamiento del síndrome de Rett
EP3570940B1 (en) 2017-01-20 2023-12-13 Prilenia Neurotherapeutics Ltd. Pridopidine for use in the treatment of fragile x syndrome
EA202090510A1 (ru) 2017-08-14 2020-06-08 Приления Ньюротерапьютикс Лтд. Способ лечения бокового амиотрофического склероза придопидином
MX383462B (es) 2017-09-08 2025-03-14 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos

Also Published As

Publication number Publication date
AU2017315781B2 (en) 2021-01-28
MX2019002190A (es) 2019-09-11
DK3503890T3 (da) 2025-01-27
JP2021119189A (ja) 2021-08-12
WO2018039475A1 (en) 2018-03-01
JP7278210B2 (ja) 2023-05-19
CA3035099A1 (en) 2018-03-01
BR112019003731A2 (pt) 2019-07-16
CN110012661A (zh) 2019-07-12
JP7278327B2 (ja) 2023-05-19
AU2017315781A1 (en) 2019-04-11
US20190192496A1 (en) 2019-06-27
CA3035099C (en) 2023-01-17
EP3503890A1 (en) 2019-07-03
EP3503890A4 (en) 2020-05-06
US20240075021A1 (en) 2024-03-07
WO2018039475A8 (en) 2018-10-04
US11826361B2 (en) 2023-11-28
JP2019524897A (ja) 2019-09-05
ES3009437T3 (en) 2025-03-26
EP3503890B1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
IL281793A (en) Use of cannabinoids in the treatment of epilepsy
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
IL257105A (en) Modified cells and methods of therapy
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
EP3551285C0 (en) DEFIBRILLATOR
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
PL3265053T3 (pl) Sposoby leczenia skóry
EP3411412A4 (en) FIT-IMMUNOGLOBULIN TECHNOLOGY AND USES THEREOF
EP3564335A4 (en) SURFACE TREATMENT AGENT
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
DK3474802T3 (da) Medicinsk forbinding
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
DK3778595T3 (da) Pancreatitisbehandling
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
EP3448263A4 (en) Electrotherapeutic treatment
DK3231444T3 (da) Ny behandling
EP3481952A4 (en) METHYLATION MARKERS IN THE TREATMENT OF LEUKEMIA AND USES THEREOF
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej
EP3508550A4 (en) POLISHING COMPOSITION AND POLISHING COMPOSITION ASSEMBLY
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3408265T3 (da) Terapeutiske forbindelser
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii